行情

ALKS

ALKS

阿尔凯默斯
NASDAQ

实时行情|Nasdaq Last Sale

18.58
+0.06
+0.30%
盘后: 18.60 +0.02 +0.11% 16:20 01/22 EST
开盘
18.50
昨收
18.53
最高
18.83
最低
18.38
成交量
224.30万
成交额
--
52周最高
37.75
52周最低
17.11
市值
29.27亿
市盈率(TTM)
-14.4828
分时
5日
1月
3月
1年
5年

分析师评级

12位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ALKS 新闻

  • Alkermes Option Alert: Feb 21 $18 Puts at the Bid: 2607 @ $0.5 vs 13 OI; Earnings 2/13 Before Open [est] Ref=$19.465
  • Benzinga.5天前
  • Alkermes (ALKS) Stock Sinks As Market Gains: What You Should Know
  • Zacks.6天前
  • Hedge Fund Favorites vs. Alkermes Plc (ALKS) In 2019
  • Insider Monkey.01/13 14:40
  • Does Alkermes plc (NASDAQ:ALKS) Have A High Beta?
  • Simply Wall St..01/13 10:11

更多

所属板块

生物技术和医学研究
+0.13%
制药与医学研究
-0.23%

热门股票

名称
价格
涨跌幅

ALKS 简况

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
展开

Webull提供Alkermes Plc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。